Earlier on Tuesday, Soleno Therapeutics Inc (NASDAQ: SLNO) released top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (PWS).
Cantor Fitzgerald raised the price target on Soleno Therapeutics from $19 to $35, with an Overweight rating.
The analysts Kristen Kluska, Richard Miller, and Jason Bouvier note that the trial outcome is as good as could have been expected.
The analysts say the data suggests promising signals regarding the treatment's durability.
The analyst ...